House passes 21st Century Cures Act; Omeros snags EU recommendation for Omidria;

@FierceBiotech: Amgen's PCSK9 contender lines up for first place in the blockbuster EU race. Story | Follow @FierceBiotech

@JohnCFierce: What's your list of top 5 public biotechs? (Potential, management, smart execution) I'd put $BLUE in that group. Any other suggestions? | Follow @JohnCFierce

> The U.S. House of Representatives signed off on the the 21st Century Cures Act, a bill designed to speed the path of new medicines by increasing funding to the FDA and NIH. Story

> The European Medicines Agency's Committee for Medicinal Products for Human Use recommended Omeros' eye drug ($OMER) Omidria for approval. News

> GlaxoSmithKline ($GSK) submitted its asthma antibody mepolizumab for Japanese approval. More

Medical Device News

@FierceMedDev: Neuwave Medical reels in $25M for minimally invasive ablation device. Story | Follow @FierceMedDev

@VarunSaxena2: Issue that led to halt of St. Jude TAVR trial no cause for concern, EuroPCR experts say $STJ. More | Follow @VarunSaxena2

@EmilyWFierce: $MDT CEO Omar Ishrak on the company's strategy in #India: Article | Follow @EmilyWFierce

> India developing federal medical device surveillance system. News

> Report: Researchers develop neuron chips to direct movement of robotic prosthetics. More

Pharma News

@FiercePharma: Chicken producer Sanderson says FDA's crackdown on antibiotics lacks 'reliable science.' Article | Follow @FiercePharma

@EricPFierce: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of  0.9% sodium chloride. More | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday - Report: Cadila next in line for injectables bulk-up as it nears deal for Claris. Story | Follow @CarlyHFierce

> Celgene's next-gen psoriasis drug dissed by German cost watchdog. News

> England's Cancer Drugs Fund keeps Bayer's Stivarga, axes Eisai and Lilly meds. More

Suggested Articles

MPM and Dana-Farber have formed a venture philanthropy alliance, raising a $100 million fund and $26 million in donations to support basic research.

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.